Immunomedics, Inc. (IMMU) Announces Orphan Drug Designation For IMMU-132 For Pancreatic Cancer Therapy
6/9/2014 8:59:56 AM
MORRIS PLAINS, N.J., June 9, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that IMMU-132, the Company's antibody-drug conjugate (ADC) for solid cancer therapy, has received orphan drug status from the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by